NCT00651664View on ClinicalTrials.gov

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 22, 2007

Primary Completion Date

September 1, 2010

Study Completion Date

April 5, 2011

Conditions
Advanced Malignancies
Interventions
DRUG

alisertib

Alisertib (MLN8237) capsules

Trial Locations (2)

08035

Ciutat Sanitaria Vall d'Hebron - Servicio de Oncologia, Barcelona

Unknown

H. Clínico Universitario de Valencia, Valencia

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00651664 - A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies | Biotech Hunter | Biotech Hunter